Company intelligence / Profile preview
Servatus Biopharmaceuticals
- Ownership
- Private
- Employees
- ~35
- Development stage
- Phase 1
Overview
Servatus has achieved key clinical milestones indicating potential to change treatment paradigms for severe autoimmune diseases. The company has reported positive results in early clinical studies for insomnia and IBS-C. Its LBP program includes a Phase I trial for H. pylori infection and Phase II trials in autoimmune/inflammatory conditions. The company also produces OTC microbiome-based products targeting skin health and GI symptoms.
- Therapeutic areas
- GastroenterologyPsychiatryImmunologyInfectious Diseases
- Modalities
- Live biotherapeutic products (LBPs)Engineered/modified proteins
- Industry
- Biotech
Drug pipeline
10 assets9 more assets in the full pipeline.
Request access →Partnerships
Beyond the preview
Go deeper on Servatus Biopharmaceuticals.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Servatus Biopharmaceuticals.